Omega-3 (EPA/DHA) vs Serrapeptase
A side-by-side research comparison of Omega-3 (EPA/DHA) and Serrapeptase across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Omega-3 (EPA/DHA) | Serrapeptase |
|---|---|---|
| Full name | Omega-3 Fatty Acids (EPA + DHA) | Serrapeptase (Serratiopeptidase) |
| Category | Cardiovascular | Cardiovascular |
| Status | Dietary supplement / FDA-approved (Rx fish oil) | Dietary supplement |
| Mechanism | EPA/DHA incorporate into cell membranes, displacing arachidonic acid and reducing pro-inflammatory eicosanoid production. Generate resolvins and protectins for active inflammation resolution. Activate PPARγ and inhibit NF-κB. | Degrades non-living tissue including fibrin, blood clots, mucus, and arterial plaque without harming living cells. Inhibits bradykinin release and reduces prostaglandin synthesis for anti-inflammatory effects. |
| Molecular weight | EPA: 302.45 Da, DHA: 328.49 Da | ~52,000 Da |
| Half-life | ~48-72 hours (membrane incorporation) | ~4-6 hours |
| Bioavailability | Triglyceride form: ~70%; ethyl ester: ~30-40%; phospholipid (krill): ~85% | Oral (enteric-coated required); detectable in bloodstream |
| Typical dose | 2-4g combined EPA+DHA | 120,000-240,000 SPU |
| Frequency | Daily with meals | Daily on empty stomach |
| Route | Oral (softgel, liquid) | Oral (enteric-coated) |
Omega-3 (EPA/DHA) reported benefits
- Triglyceride reduction (25-45%)
- Anti-inflammatory (SPM production)
- Cardiac rhythm stabilization
- Brain and cognitive support
- Joint inflammation reduction
- Membrane fluidity optimization
Serrapeptase reported benefits
- Reduced inflammation and swelling
- Arterial plaque modulation
- Mucus/biofilm breakdown
- Post-surgical recovery
- Sinus/respiratory clearing
- Pain reduction
Related comparisons
Research and educational reference only. Not medical advice.